Skip Nav Destination
Issues
Phase I Study of High-Dose l-Methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH Wild-Type High-Grade Glioma
Lucas A. Salas; Thomas G. Stewart; Bret C. Mobley; Chengwei Peng; Jing Liu; Sudan N. Loganathan; Jialiang Wang; Yanjun Ma; Mitchel S. Berger; Devin Absher; Yang Hu; Paul L. Moots; Brock C. Christensen; Stephen W. Clark
An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations
Deepankar Chakroborty; Veera K. Ojala; Anna M. Knittle; Jasmin Drexler; Mahlet Z. Tamirat; Regina Ruzicka; Karin Bosch; Johanna Woertl; Susanne Schmittner; Laura L. Elo; Mark S. Johnson; Kari J. Kurppa; Flavio Solca; Klaus Elenius
A Randomized Clinical Trial of Precision Prevention Materials Incorporating MC1R Genetic Risk to Improve Skin Cancer Prevention Activities Among Hispanics
John Charles A. Lacson; Scarlet H. Doyle; Jocelyn Del Rio; Stephanie M. Forgas; Rodrigo Carvajal; Guillermo Gonzalez-Calderon; Adriana Ramírez Feliciano; Youngchul Kim; Richard G. Roetzheim; Steven K. Sutton; Susan T. Vadaparampil; Brenda Soto-Torres; Peter A. Kanetsky
Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation
Sophie Wildsmith; Jiabu Ye; April Franks; Giovanni Melillo; Jon Armstrong; Jessica Whiteley; Karina Schnittker; Fangru Lian; Bryan Roland; Constantine Sabalos; Payam Ahmadi; Jerome Fayette; Caroline Even; Ricard Mesía; Lillian L. Siu; Dan P. Zandberg; Jill Walker
Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen Selectivity
Talar Tokatlian; Grace E. Asuelime; Martin S. Naradikian; Jee-Young Mock; Mark E. Daris; Aaron D. Martin; Dora Toledo Warshaviak; Alexander Kamb; Agnes E. Hamburger
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds